Synthesis and antitumor activity of camptothecin- 4β-triazolopodophyllotoxin conjugates

References

• Bielawski K, Winnicka K, Bielawska A. 2006. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull. 29:1493–1497.
   PubMed Web of Science ®Google Scholar
• Chen GL, Yang L, Towe TC, Halligan BD, Tewey KM, Liu LF. 1984. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian topoisomerase II. J Biol Chem. 259:13560–13566.
   PubMed Web of Science ®Google Scholar
• Chang JY, Guo X, Chen HX, Jiang ZL, Fu Q, Wang HK, Bastow KF, Zhu XK, Guan J, Lee KH, Cheng YC. 2000. Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4b-Amino-49-Odemethylepipodophyllotoxin conjugates. Biochem Pharmacol. 59:497–508.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Bisaria VS, Panda AK, Srivastava AK. 2004. Cytotoxicity of in vitro produced podophyllotoxin from podophyllum hexandrum on human cancer cell line. Nat Prod Res. 18:51–57.
   PubMed Web of Science ®Google Scholar
• Delgado JL, Hsieh CM, Chan NL, Hiasa H. 2018. Topoisomerases as anticancer targets. Biochem J. 475:373–398.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyam T, Ariyoshi Y, Negoro S, Masuda NJ. 1992. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. Clin Oncol. 10:16–20.
   Web of Science ®Google Scholar
• Gellert M, Mizuuchi K, O’Dea MH, Nash HA. 1976. DNA gyrase: An enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A. 73:3872–3876.
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Lihou MG, Liu LF. 1989. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077–5082.
   PubMed Web of Science ®Google Scholar
• Hansen HF, Jesen RB, Willumsen AM, Norsko-Lauritsen N, Ebbesen P, Nielen PE, Buchardt O. 1993. New compounds related to podophyllotoxin and congeners: Synthesis, structure elucidation and biological testing. Acta Chem Scand. 47:1190–1200.
   PubMedGoogle Scholar
• Johnson PK, McCabe FL, Faucette LF, Hertzberg RP, Kingsbury WD, Boehm JC, Caranfa MJ, Holden KG. 1989. SK & F 104864, a water soluble analog of camptothecin with a broad spectrum of activity in preclinical tumor models. Proc Am Assoc Cancer Res. 30:623.
   Google Scholar
• Kamal A, Laxman N, Ramesh G. 2000. Facile and efficient one-pot synthesis of 4β-arylaminopodophyllotoxins: Synthesis of DNA topoisomerase II inhibitors (NPF and W-68). Bioorg Med Chem Lett. 10:2059–2062.
   PubMed Web of Science ®Google Scholar
• Onawolea AT, Sulaimana KO, Adegokeb RO, Kolapo TU. 2017. Identification of potential inhibitors against the Zika virus usingconsensus scoring. J Mol Graphics Modell. 73:54–61.
   Google Scholar
• Pajouhesh H, Lenz GR. 2005. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2:541–553.
   PubMedGoogle Scholar
• Reddy VG, Bonam SR, Reddy TS, Akunuri R, Naidu VGM, Nayak VL, Bhargava Sk, Kumar HMS, Srihari P, Kamal A. 2018. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer. Eur J Med Chem. 144:595–611.
   PubMed Web of Science ®Google Scholar
• Ross R, Rowe T, Glissom B, Yalowich J, Liu LF. 1984. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 44:5857–5860.
   PubMed Web of Science ®Google Scholar
• Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. 2002. A stepwise huisgen cycloaddition process: Copper (I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew Chem Int Ed. 114:2708–2711.
   Google Scholar
• Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. 2005. Camptothecin and its analogues: A review on their chemotherapeutic potential. Nat Prod Res. 19:393–412.
   PubMed Web of Science ®Google Scholar
• Terada T, Fujimoto K, Nomura M, Yamashita J, Wierzba K, Yamazaki R, Shibata J, Sugimoto Y, Yamada Y, Kobunai T, Takeda S, Minami Y, Yoshida K, Yamaguchi H. 1993. Antitumor agents. 3. Synthesis and biological activity of 4. beta.-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents. J Med Chem. 36:1689–1699.
   PubMed Web of Science ®Google Scholar
• Tawa R, Takami M, Imakura Y, Lee KH. 1997. Effects of CpG methylation to double stranded DNA breaks by Cu (II)-podophyllotoxin derivative complexes. Bioorg Med Chem Lett. 7:489–494.
   Web of Science ®Google Scholar
• Tsao YP, Russo A, Nyamuswa G, Sibler R and Liu LF. 1993. Interaction between replication fork and topoisomerase-I DNA cleavable complexes. Study in a cell-free SV40 DNA replication system. Cancer Res. 53:5908–5914.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd H, Rose S. 2008. Quantitative approaches to structure–activity relationships. In: . The Practice of Medicinal Chemistry. 3rd ed. Cambridge, MA: Academic Press; p. 491–513.
   Google Scholar
• Wang JC. 2002. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev. 3:430–440.
   Google Scholar
• Wang JC. 1971. Interaction between DNA and an Escherichia coli protein ω. 55:523–533.
   Google Scholar
• Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim G. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc. 88:3888–3890.
   Web of Science ®Google Scholar
• Xiao Z, Xiao YD, Feng J, Golbraikh A, Tropsha A, Lee KH. 2002. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR method. J Med Chem. 45:2294–2309.
   PubMed Web of Science ®Google Scholar
• Ye DY, Shi Q. Leung CH, Kim SW, Park SY, Gullen EA, Jiang ZL, Zhu H, Morris-Natschke SL, Cheng YC, Lee KH. 2012. Antitumor agents 294. Novel E-ring-modified camptothecin–4b-anilino-40-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents. Bioorg Med Chem. 20:4489–4494.
   PubMed Web of Science ®Google Scholar
• Zi CT, Xu FQ, Li GT, Li Y, Ding ZT, Zhou J, Jiang ZH, Hu JM. 2013. Synthesis and anticancer activity of glucosylated podophyllotoxin derivatives linked via 4β-Triazole Rings. Molecules 18:13992–14012.
   PubMed Web of Science ®Google Scholar
• Zi CT, Liu ZH, Li GT, Li Y, Zhou J, Ding ZT, Hu JM, Jiang JH. 2015. Synthesis, and cytotoxicity of perbutyrylated glycosides of 4β-triazolopodophyllotoxin derivatives. Molecules 20:3255–3280.
   PubMed Web of Science ®Google Scholar
• Zi CT, Li GT, Li Y, Zhou J, Ding ZT, Jiang JH, Hu JM. 2015. Synthesis and anticancer activity of 4β-triazole-podophyllotoxin glycosides. Nat Prod Bioprosp. 5:83–90.
   Web of Science ®Google Scholar
• Zi CT, Yang L, Gao W, Li Y, Zhou J, Ding ZT, Hu JM, Jiang ZH. 2017. Click glycosylation for the synthesis of 1,2,3-Triazole-linked picropodophyllotoxin glycoconjugates and their anticancer activity. ChemistrySelect 2:5038–5044.
   Web of Science ®Google Scholar